MARKET

EVFM

EVFM

Evofem
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.990
-0.050
-1.64%
Pre Market: 3.230 +0.24 +8.03% 06:03 08/03 EDT
OPEN
3.080
PREV CLOSE
3.040
HIGH
3.110
LOW
2.940
VOLUME
3.50M
TURNOVER
--
52 WEEK HIGH
7.50
52 WEEK LOW
2.730
MARKET CAP
233.64M
P/E (TTM)
-1.5639
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average EVFM stock price target is 15.00 with a high estimate of 25.00 and a low estimate of 9.00.

EPS

EVFM News

More
Evofem Biosciences to Report Second Quarter 2020 Results and Provide Corporate Update on Tuesday, August 4, 2020
Evofem Biosciences, Inc. (NASDAQ: EVFM) will hold a webcast and conference call to discuss the Company's financial results and business highlights for the second quarter ended June 30, 2020.
PR Newswire · 07/23 12:30
Edited Transcript of EVFM.OQ earnings conference call or presentation 6-Aug-19 3:00pm GMT
Q2 2019 Evofem Biosciences Inc Earnings Call
Thomson Reuters StreetEvents · 07/21 07:55
Evofem Biosciences Highlights Peer-Reviewed Publication Of Pivotal Phase 3 AMPOWER Study Results For Phexxi (lactic acid, citric acid and potassium bitartrate) In Contraception
SAN DIEGO, July 15, 2020 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ:EVFM), a commercial-stage biopharmaceutical company, today announced that Contraception, an international, peer-reviewed, reproductive health
Benzinga · 07/15 12:33
Evofem Biosciences Announces Peer-Reviewed Publication of the Pivotal Phase 3 AMPOWER Study Results For Phexxi™ (lactic acid, citric acid and potassium bitartrate) in Contraception
Evofem Biosciences, Inc. (NASDAQ: EVFM), a commercial-stage biopharmaceutical company, today announced that Contraception, an international, peer-reviewed, reproductive health journal, published the primary efficacy and safety results from the Phase 3 AMPOWER
PR Newswire · 07/15 12:30
Evofem Biosciences Issues Mid-Year 2020 Letter to Stockholders
PR Newswire · 07/01 13:01
Are Options Traders Betting on a Big Move in Evofem Biosciences (EVFM) Stock?
Zacks · 06/29 14:33
Evofem Biosciences (EVFM) Looks Good: Stock Adds 10.1% in Session
Zacks · 06/26 13:44
The Daily Biotech Pulse: GlaxoSmithKline, IDEAYA Strike Oncology Partnership, Decision Day For Merck, Adverum's New CEO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 16)
Benzinga · 06/16 12:15

Industry

Pharmaceuticals
-0.80%
Pharmaceuticals & Medical Research
-1.15%

Hot Stocks

Symbol
Price
%Change

About EVFM

Evofem Biosciences Inc, formerly Neothetics, Inc., is a clinical-stage specialty biopharmaceutical company. The Company develops products to address unmet needs in women's sexual and reproductive health. The Company’s product Amphora, is a Multipurpose Vaginal pH Regulator (MVP-R) designed to regulate vaginal pH to within the normal range of 3.5 to 4.5 even in the presence of semen. This maintains an acidic environment which is inhospitable to sperm as well as certain viral and bacterial pathogens associated with sexually transmitted infections. Amphora is used to prevent urogenital chlamydia and gonorrhea in women. The Company is in the second Phase III clinical trial of Amphora for prevention of pregnancy (AMP002). The Company is currently designing a Phase IIb trial for its second product candidate, a MVP-R to reduce the recurrence of bacterial vaginosis.
More

Webull offers kinds of Evofem Biosciences Inc stock information, including NASDAQ:EVFM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EVFM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EVFM stock methods without spending real money on the virtual paper trading platform.